We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 21, 2022

Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy for Locally Advanced and Borderline Resectable Pancreatic Cancer

International Journal of Radiation Oncology, Biology, Physics

 

Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Radiation Oncology, Biology, Physics
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation
Int. J. Radiat. Oncol. Biol. Phys 2022 Jul 18;[EPub Ahead of Print], EJ Koay, M Zaid, M Aliru, P Bagereka, A Van Wieren, MJ Rodriguez, G Jacobson, RA Wolff, M Overman, G Varadhachary, S Pant, H Wang, CW Tzeng, N Ikoma, M Kim, JE Lee, MH Katz, E Tamm, P Bhosale, CM Taniguchi, EB Holliday, GL Smith, EB Ludmir, BD Minsky, CH Crane, AC Koong, P Das, X Wang, M Javle, S Krishnan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading